Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma

被引：32

作者：

Azuaje, Francisco ^{[1
]}

Tiemann, Katja ^{[1
]}

Niclou, Simone P. ^{[1
]}

机构：

[1] LIH, Dept Oncol, NorLux Neurooncol Lab, Luxembourg, Luxembourg

来源：

CELL COMMUNICATION AND SIGNALING | 2015年 / 13卷

关键词：

Epidermal growth factor receptor (EGFR); Targeted therapies; Resistance to treatment; Glioblastoma; Systems biology; GROWTH-FACTOR-RECEPTOR; PHASE-II TRIAL; KINASE INHIBITORS; TARGETED THERAPIES; LUNG-CANCER; TYROSINE KINASES; TUMOR-SUPPRESSOR; MUTANT EGFRVIII; GLIOMA; ACTIVATION;

D O I：

10.1186/s12964-015-0098-6

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The alteration of the epidermal growth factor receptor (EGFR)-driven signaling network is a characteristic feature of glioblastomas (GBM), and its inhibition represents a treatment strategy. However, EGFR-targeted interventions have been largely ineffective. Complex perturbations in this system are likely to be central to tumor cells with high adaptive capacity and resistance to therapies. We review key concepts and mechanisms relevant to EGFR-targeted treatment resistance at a systems level. Our understanding of treatment resistance as a systems-level phenomenon is necessary to develop effective therapeutic options for GBM patients. This is allowing us to go beyond the notion of therapeutic targets as single molecular components, into strategies that can weaken cancer signaling robustness and boost inherent network-level vulnerabilities.

引用

页数：13

共 50 条

[21] Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy [J].

Chen, Fan ;

Liu, Jinpeng ;

Flight, Robert M. ;

Naughton, Kassandra J. ;

Lukyanchuk, Alexsandr ;

Edgin, Abigail R. ;

Song, Xiulong ;

Zhang, Haikuo ;

Wong, Kwok-Kin ;

Moseley, Hunter N. B. ;

Wang, Chi ;

Brainson, Christine F. .

ADVANCED SCIENCE, 2021, 8 (22)

[22] Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma [J].

Ronellenfitsch, Michael W. ;

Zeiner, Pia S. ;

Mittelbronn, Michel ;

Urban, Hans ;

Pietsch, Torsten ;

Reuter, Dirk ;

Senft, Christian ;

Steinbach, Joachim P. ;

Westphal, Manfred ;

Harter, Patrick N. .

ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 :81

[23] Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma [J].

Gao, Qinglei ;

Lei, Ting ;

Ye, Fei .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) :1023-1040

[24] BGB324 effectively overcomes AXL-mediated resistance to osimertinib in preclinical model of EGFR-driven lung cancer [J].

Xie, Mian ;

Wu, Xiao-Jun ;

Li, Xiang-xiang ;

Gu, Ying-ying .

CANCER SCIENCE, 2018, 109 :918-918

[25] FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth [J].

Niu, Mengmeng ;

Xu, Jing ;

Liu, Yang ;

Li, Yuhuang ;

He, Tao ;

Ding, Liangping ;

He, Yajun ;

Yi, Yong ;

Li, Fengtian ;

Guo, Rongtian ;

Gao, Ya ;

Li, Rui ;

Li, Luping ;

Fu, Mengyuan ;

Hu, Qingyong ;

Luo, Yangkun ;

Zhang, Chunyan ;

Qin, Kewei ;

Yi, Jianqiao ;

Yu, Shuhan ;

Yang, Jian ;

Chen, Hu ;

Wang, Liang ;

Li, Zhonghan ;

Dong, Biao ;

Qi, Shiqian ;

Liang Ouyang ;

Zhang, Yujun ;

Cao, Yang ;

Xiao, Zhi-Xiong Jim .

NATURE COMMUNICATIONS, 2021, 12 (01)

[26] Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ [J].

Schulte, Alexander ;

Liffers, Katrin ;

Kathagen, Annegret ;

Riethdorf, Sabine ;

Zapf, Svenja ;

Merlo, Adrian ;

Kolbe, Katharina ;

Westphal, Manfred ;

Lamszus, Katrin .

NEURO-ONCOLOGY, 2013, 15 (10) :1289-1301

[27] EGFR-Targeted Therapy Alters the Tumor Microenvironment In EGFR-Driven Lung Tumors: Rationale for Combination Therapies [J].

Jia, Y. ;

Jiang, T. ;

Li, X. ;

Zhao, C. ;

Zhou, C. ;

Zhao, S. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S457-S457

[28] InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma [J].

Ma, Yufang ;

Tang, Nan ;

Thompson, Reid C. ;

Mobley, Bret C. ;

Clark, Steven W. ;

Sarkaria, Jann N. ;

Wang, Jialiang .

CLINICAL CANCER RESEARCH, 2016, 22 (07) :1767-1776

[29] Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme [J].

Jun, H. J. ;

Acquaviva, J. ;

Chi, D. ;

Lessard, J. ;

Zhu, H. ;

Woolfenden, S. ;

Bronson, R. T. ;

Pfannl, R. ;

White, F. ;

Housman, D. E. ;

Iyer, L. ;

Whittaker, C. A. ;

Boskovitz, A. ;

Raval, A. ;

Charest, A. .

ONCOGENE, 2012, 31 (25) :3039-3050

[30] Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches [J].

Singh, Gursimran ;

Rohit, Pankaj ;

Kumar, Pankaj ;

Aran, Khadga Raj .

MEDICAL ONCOLOGY, 2025, 42 (04)

← 1 2 3 4 5 →